Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Thymocytes and T lymphocytes.|
|Storage buffer||PBS with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, store in dark, DO NOT FREEZE!|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||20ul/10^6 cells|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 2 publications below|
CD59 (Protectin) is a small (18-20 kDa) GPI-anchored ubiquitously expressed inhibitor of the membrane attack complex (MAC). It is thus the key regulator that preserves the autologous cells from terminal effector mechanism of the complement cascade. CD59 associates with C5b-8 complex and thereby counteracts appropriate formation of cytolytic pore within the plasma membrane. CD59 is also an low-affinity ligand of human CD2 and causes T cell costimulation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling.
MA1-19576 was used in flow cytometry to use flow cytometry to characterize 123 cases of B-cell chronic lymphocytic leukemia
|Zucchetto A,Sonego P,Degan M,Bomben R,Dal Bo M,Russo S,Attadia V,Rupolo M,Buccisano F,Del Principe MI,Del Poeta G,Pucillo C,Colombatti A,Campanini R,Gattei V||Journal of cellular physiology (204:113)||2005|
|Not Applicable||Not Cited||
Identification of unsuspected PNH-type cells in flow cytometric immunophenotypic analysis of peripheral blood and bone marrow.
MA1-19576 was used in flow cytometry to use flow cytometry to characterize cells from patients with paroxysmal nocturnal hemoglobinuria
|Thomason RW,Papiez J,Lee RV,Szczarkowski W||American journal of clinical pathology (122:128)||2004|
16.3A5; 1F5; 1F5 antigen; 20 kDa homologous restriction factor; CD59; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 glycoprotein; CD59 molecule complement regulatory protein; CD59 molecule, complement regulatory protein; EJ16; EJ30; EL32; G344; HRF-20; HRF20; human leukocyte antigen MIC11; Ly-6-like protein; lymphocytic antigen CD59/MEM43; MAC-inhibitory protein; MAC-IP; MACIF; MEM43; MEM43 antigen; membrane attack complex (MAC) inhibition factor; Membrane attack complex inhibition factor; Membrane inhibitor of reactive lysis; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20; Protectin; surface anitgen recognized by monoclonal antibody 16.3A5; T cell-activating protein
16.3A5; 1F5; CD59; EJ16; EJ30; EL32; G344; HRF-20; HRF20; MAC-IP; MACIF; MEM43; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20